Research programme: Proto oncogene proteins c-akt inhibitors - ProlX

Drug Profile

Research programme: Proto oncogene proteins c-akt inhibitors - ProlX

Alternative Names: Protein kinase B inhibitors - ProlX; PX-316

Latest Information Update: 08 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProlX Pharmaceuticals
  • Class Sugar alcohols
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Brain cancer

Most Recent Events

  • 31 Oct 2006 ProlX Pharmaceuticals has been acquired by Biomira
  • 02 Aug 2006 This programme is still in active development
  • 28 Nov 2003 Preclinical trials in Brain cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top